More effective assessment of adverse effects and comorbidities in epilepsy: Results of a Phase II communication study

John M. Stern; David M. Labiner; Frank G. Gilliam; Patricia E. Penovich; Meaghan Onofrey; Corey A. Eagan; Gregory L. Holmes

doi:10.1016/j.yebeh.2011.06.007

More effective assessment of adverse effects and comorbidities in epilepsy: Results of a Phase II communication study

John M. Stern, David M. Labiner, Frank G. Gilliam, Patricia E. Penovich, Meaghan Onofrey, Corey A. Eagan, Gregory L. Holmes

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Research was conducted to evaluate conversations about epilepsy between community-based neurologists and patients. Adverse effects of antiepileptic drugs and mood/behavioral issues were infrequently discussed, and neurologists and patients disagreed about these issues postvisit. Follow-up research was conducted to assess the impact of a previsit assessment tool on discussions of epilepsy. Twenty neurologists reviewed a tool incorporating questions from validated instruments (Adverse Events Profile [AEP] and Neurological Disorders Depression Inventory for Epilepsy [NDDI-E]). Naturally occurring interactions between neurologists and 60 patients were recorded. Neurologists and patients were interviewed separately. All components were transcribed and analyzed using sociolinguistics. Using the previsit assessment tool increased the number of discussions about adverse effects and mood/behavioral issues and increased neurologist-patient agreement about issues postvisit. Visit length did not increase significantly when the tool was used. Ten months after follow-up research, 50% of neurologists reported continuing to use the tool in everyday practice with patients with epilepsy.

Original language	English (US)
Pages (from-to)	552-556
Number of pages	5
Journal	Epilepsy and Behavior
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.yebeh.2011.06.007
State	Published - Nov 2011

Keywords

Behavior
Communication
Comorbidities
Dialogue
Epilepsy
Linguistics
Misalignment
Mood
Side effects

ASJC Scopus subject areas

Neurology
Clinical Neurology
Behavioral Neuroscience

Access to Document

10.1016/j.yebeh.2011.06.007

Cite this

@article{7d593d2ad9884484b5a7bc8490b1af58,

title = "More effective assessment of adverse effects and comorbidities in epilepsy: Results of a Phase II communication study",

abstract = "Research was conducted to evaluate conversations about epilepsy between community-based neurologists and patients. Adverse effects of antiepileptic drugs and mood/behavioral issues were infrequently discussed, and neurologists and patients disagreed about these issues postvisit. Follow-up research was conducted to assess the impact of a previsit assessment tool on discussions of epilepsy. Twenty neurologists reviewed a tool incorporating questions from validated instruments (Adverse Events Profile [AEP] and Neurological Disorders Depression Inventory for Epilepsy [NDDI-E]). Naturally occurring interactions between neurologists and 60 patients were recorded. Neurologists and patients were interviewed separately. All components were transcribed and analyzed using sociolinguistics. Using the previsit assessment tool increased the number of discussions about adverse effects and mood/behavioral issues and increased neurologist-patient agreement about issues postvisit. Visit length did not increase significantly when the tool was used. Ten months after follow-up research, 50% of neurologists reported continuing to use the tool in everyday practice with patients with epilepsy.",

keywords = "Behavior, Communication, Comorbidities, Dialogue, Epilepsy, Linguistics, Misalignment, Mood, Side effects",

author = "Stern, {John M.} and Labiner, {David M.} and Gilliam, {Frank G.} and Penovich, {Patricia E.} and Meaghan Onofrey and Eagan, {Corey A.} and Holmes, {Gregory L.}",

note = "Funding Information: David M. Labiner is a consultant/speaker/research support for Cyberonics, Eisai, Inc., GlaxoSmithKline, Ortho–McNeil, Pfizer, Inc., and UCB and has received research grants from the Centers for Disease Control and Prevention. ",

year = "2011",

month = nov,

doi = "10.1016/j.yebeh.2011.06.007",

language = "English (US)",

volume = "22",

pages = "552--556",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - More effective assessment of adverse effects and comorbidities in epilepsy

T2 - Results of a Phase II communication study

AU - Stern, John M.

AU - Labiner, David M.

AU - Gilliam, Frank G.

AU - Penovich, Patricia E.

AU - Onofrey, Meaghan

AU - Eagan, Corey A.

AU - Holmes, Gregory L.

N1 - Funding Information: David M. Labiner is a consultant/speaker/research support for Cyberonics, Eisai, Inc., GlaxoSmithKline, Ortho–McNeil, Pfizer, Inc., and UCB and has received research grants from the Centers for Disease Control and Prevention.

PY - 2011/11

Y1 - 2011/11

N2 - Research was conducted to evaluate conversations about epilepsy between community-based neurologists and patients. Adverse effects of antiepileptic drugs and mood/behavioral issues were infrequently discussed, and neurologists and patients disagreed about these issues postvisit. Follow-up research was conducted to assess the impact of a previsit assessment tool on discussions of epilepsy. Twenty neurologists reviewed a tool incorporating questions from validated instruments (Adverse Events Profile [AEP] and Neurological Disorders Depression Inventory for Epilepsy [NDDI-E]). Naturally occurring interactions between neurologists and 60 patients were recorded. Neurologists and patients were interviewed separately. All components were transcribed and analyzed using sociolinguistics. Using the previsit assessment tool increased the number of discussions about adverse effects and mood/behavioral issues and increased neurologist-patient agreement about issues postvisit. Visit length did not increase significantly when the tool was used. Ten months after follow-up research, 50% of neurologists reported continuing to use the tool in everyday practice with patients with epilepsy.

AB - Research was conducted to evaluate conversations about epilepsy between community-based neurologists and patients. Adverse effects of antiepileptic drugs and mood/behavioral issues were infrequently discussed, and neurologists and patients disagreed about these issues postvisit. Follow-up research was conducted to assess the impact of a previsit assessment tool on discussions of epilepsy. Twenty neurologists reviewed a tool incorporating questions from validated instruments (Adverse Events Profile [AEP] and Neurological Disorders Depression Inventory for Epilepsy [NDDI-E]). Naturally occurring interactions between neurologists and 60 patients were recorded. Neurologists and patients were interviewed separately. All components were transcribed and analyzed using sociolinguistics. Using the previsit assessment tool increased the number of discussions about adverse effects and mood/behavioral issues and increased neurologist-patient agreement about issues postvisit. Visit length did not increase significantly when the tool was used. Ten months after follow-up research, 50% of neurologists reported continuing to use the tool in everyday practice with patients with epilepsy.

KW - Behavior

KW - Communication

KW - Comorbidities

KW - Dialogue

KW - Epilepsy

KW - Linguistics

KW - Misalignment

KW - Mood

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=80055018368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055018368&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2011.06.007

DO - 10.1016/j.yebeh.2011.06.007

M3 - Article

C2 - 21967731

AN - SCOPUS:80055018368

SN - 1525-5050

VL - 22

SP - 552

EP - 556

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

IS - 3

ER -

More effective assessment of adverse effects and comorbidities in epilepsy: Results of a Phase II communication study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this